vs
Dominari Holdings Inc.（DOMH）与Fortress Biotech, Inc.（FBIO）财务数据对比。点击上方公司名可切换其他公司
Dominari Holdings Inc.的季度营收约是Fortress Biotech, Inc.的1.9倍（$30.1M vs $16.1M），Fortress Biotech, Inc.净利率更高（-24.5% vs -438.1%，领先413.6%），Dominari Holdings Inc.同比增速更快（220.4% vs 6.3%），过去两年Dominari Holdings Inc.的营收复合增速更高（369.1% vs 11.0%）
堡垒生物科技（Fortress Biotech）是一家生物制药企业，核心业务为收购、开发并商业化创新医药与生物技术产品。公司由医学博士林赛·A·罗森瓦尔德担任首席执行官，包括绝大多数子公司在内，公司总部均设于佛罗里达州贝港群岛。
DOMH vs FBIO — 直观对比
营收规模更大
DOMH
是对方的1.9倍
$16.1M
营收增速更快
DOMH
高出214.1%
6.3%
净利率更高
FBIO
高出413.6%
-438.1%
两年增速更快
DOMH
近两年复合增速
11.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $30.1M | $16.1M |
| 净利润 | $-131.8M | $-3.9M |
| 毛利率 | — | 66.1% |
| 营业利润率 | -8.9% | -28.8% |
| 净利率 | -438.1% | -24.5% |
| 营收同比 | 220.4% | 6.3% |
| 净利润同比 | -12426.2% | 41.8% |
| 每股收益（稀释后） | $-6.94 | $-0.15 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DOMHFBIO
| Q4 25 | $30.1M | $16.1M | ||
| Q3 25 | $50.8M | $17.6M | ||
| Q2 25 | $34.1M | $16.4M | ||
| Q1 25 | $8.1M | $13.1M | ||
| Q4 24 | $9.4M | $15.1M | ||
| Q3 24 | $4.0M | $14.6M | ||
| Q2 24 | $6.2M | $14.9M | ||
| Q1 24 | $1.4M | $13.0M |
净利润DOMHFBIO
| Q4 25 | $-131.8M | $-3.9M | ||
| Q3 25 | $125.2M | $5.8M | ||
| Q2 25 | $16.6M | $15.5M | ||
| Q1 25 | $-32.5M | $-10.6M | ||
| Q4 24 | $1.1M | $-6.8M | ||
| Q3 24 | $-4.2M | $-12.9M | ||
| Q2 24 | $-6.1M | $-10.9M | ||
| Q1 24 | $-5.4M | $-15.4M |
毛利率DOMHFBIO
| Q4 25 | — | 66.1% | ||
| Q3 25 | — | 67.4% | ||
| Q2 25 | — | 69.9% | ||
| Q1 25 | — | 63.5% | ||
| Q4 24 | — | 69.1% | ||
| Q3 24 | — | 69.4% | ||
| Q2 24 | — | 61.6% | ||
| Q1 24 | — | 53.9% |
营业利润率DOMHFBIO
| Q4 25 | -8.9% | -28.8% | ||
| Q3 25 | -3.1% | -38.6% | ||
| Q2 25 | -57.0% | -222.2% | ||
| Q1 25 | -394.6% | -169.9% | ||
| Q4 24 | 0.4% | -158.3% | ||
| Q3 24 | -79.1% | -151.0% | ||
| Q2 24 | -44.3% | -186.5% | ||
| Q1 24 | -205.2% | -280.6% |
净利率DOMHFBIO
| Q4 25 | -438.1% | -24.5% | ||
| Q3 25 | 246.4% | 33.2% | ||
| Q2 25 | 48.7% | 94.4% | ||
| Q1 25 | -400.5% | -80.6% | ||
| Q4 24 | 11.4% | -44.7% | ||
| Q3 24 | -104.2% | -88.0% | ||
| Q2 24 | -99.1% | -73.5% | ||
| Q1 24 | -398.0% | -118.3% |
每股收益（稀释后）DOMHFBIO
| Q4 25 | $-6.94 | $-0.15 | ||
| Q3 25 | $7.27 | $0.11 | ||
| Q2 25 | $1.12 | $0.45 | ||
| Q1 25 | $-3.02 | $-0.48 | ||
| Q4 24 | $0.21 | $-0.16 | ||
| Q3 24 | $-0.67 | $-0.76 | ||
| Q2 24 | $-1.01 | $-0.73 | ||
| Q1 24 | $-0.91 | $-1.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $80.5M | $79.4M |
| 总债务越低越好 | — | $52.4M |
| 股东权益账面价值 | $69.4M | $49.9M |
| 总资产 | $112.9M | $185.5M |
| 负债/权益比越低杠杆越低 | — | 1.05× |
8季度趋势，按日历期对齐
现金及短期投资DOMHFBIO
| Q4 25 | $80.5M | $79.4M | ||
| Q3 25 | $176.2M | $86.2M | ||
| Q2 25 | $28.2M | $74.4M | ||
| Q1 25 | $18.9M | $91.3M | ||
| Q4 24 | $8.2M | $57.3M | ||
| Q3 24 | $7.2M | $58.9M | ||
| Q2 24 | $12.1M | $76.2M | ||
| Q1 24 | $7.1M | $83.8M |
总债务DOMHFBIO
| Q4 25 | — | $52.4M | ||
| Q3 25 | — | $47.8M | ||
| Q2 25 | — | $50.0M | ||
| Q1 25 | — | $56.4M | ||
| Q4 24 | — | $58.0M | ||
| Q3 24 | — | $52.5M | ||
| Q2 24 | — | $67.0M | ||
| Q1 24 | — | $61.4M |
股东权益DOMHFBIO
| Q4 25 | $69.4M | $49.9M | ||
| Q3 25 | $210.2M | $55.9M | ||
| Q2 25 | $88.6M | $43.9M | ||
| Q1 25 | $42.4M | $22.3M | ||
| Q4 24 | $39.9M | $22.7M | ||
| Q3 24 | $38.3M | $21.2M | ||
| Q2 24 | $42.4M | $17.9M | ||
| Q1 24 | $47.7M | $23.0M |
总资产DOMHFBIO
| Q4 25 | $112.9M | $185.5M | ||
| Q3 25 | $223.4M | $181.4M | ||
| Q2 25 | $109.3M | $159.9M | ||
| Q1 25 | $52.3M | $178.1M | ||
| Q4 24 | $47.1M | $144.2M | ||
| Q3 24 | $43.4M | $127.1M | ||
| Q2 24 | $49.1M | $145.7M | ||
| Q1 24 | $52.2M | $164.6M |
负债/权益比DOMHFBIO
| Q4 25 | — | 1.05× | ||
| Q3 25 | — | 0.86× | ||
| Q2 25 | — | 1.14× | ||
| Q1 25 | — | 2.53× | ||
| Q4 24 | — | 2.55× | ||
| Q3 24 | — | 2.48× | ||
| Q2 24 | — | 3.75× | ||
| Q1 24 | — | 2.67× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $22.7M | $-12.5M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流DOMHFBIO
| Q4 25 | $22.7M | $-12.5M | ||
| Q3 25 | $-4.9M | $-6.1M | ||
| Q2 25 | $-353.0K | $-27.6M | ||
| Q1 25 | $1.2M | $-19.6M | ||
| Q4 24 | $-16.7M | $-12.9M | ||
| Q3 24 | $-4.7M | $-20.1M | ||
| Q2 24 | $1.4M | $-21.8M | ||
| Q1 24 | $-8.6M | $-25.4M |
资本支出强度DOMHFBIO
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金转化率DOMHFBIO
| Q4 25 | — | — | ||
| Q3 25 | -0.04× | -1.04× | ||
| Q2 25 | -0.02× | -1.78× | ||
| Q1 25 | — | — | ||
| Q4 24 | -15.65× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DOMH
| Chief Operating Decision Maker | $30.1M | 100% |
| Commissions | $458.0K | 2% |
FBIO
暂无分部数据
